News
Canada approves Myfembree for the management of endometriosis
Myfembree was approved by the US FDA for the management of endometriosis in August 2022

Health Canada, the department of the Canadian government responsible for national health policy, has approved the drug Myfembree for the management of endometriosis.
Sumitomo Pharma Canada and Pfizer Canada have announced that Health Canada has granted a Notice of Compliance (NOC) for the drug for the management of moderate to severe pain associated with endometriosis.
An NOC is issued following the satisfactory review of a submission for a new drug, and signifies compliance with the Canadian food and drug regulations.
Health Canada has also approved the same drug for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
The combination therapy oral treatment is taken once daily and is hoped to provide a new option for women to manage their symptoms related to endometriosis and uterine fibroids.
Lisa Mullett, general manager at Sumitomo Pharma Canada, said: “Health Canada’s approval of Myfembree across the uterine fibroid and endometriosis indications marks a significant milestone in our commitment to women’s health.
“These are multi-faceted and complex chronic conditions, and we are proud to make new treatment options available to women in Canada.”
Andréa Mueller, primary care portfolio lead at Pfizer Canada, said: “Myfembree’s approval is a testament to the shared commitment between our two companies to support women’s health.
“We are proud to help women manage their health at all stages of their lives.”
Myfembree was approved by the US Food and Drug Administration (FDA) for the treatment of heavy menstrual bleeding associated with uterine fibroids in May 2021 and for the management of moderate to severe pain associated with endometriosis in August 2022.
The approval of the drug in Canada was based on several Phase 3 studies, including the LIBERTY 1 and LIBERTY 2 trials for uterine fibroids and the SPIRIT 1 and SPIRIT 2 trials for endometriosis.
Pfizer Canada says it will lead commercialisation efforts of Myfembree in the uterine fibroid and endometriosis indications. In partnership with Sumitomo Pharma in Canada, the pharma giant will assess the timeline of availability for Myfembree.
Dr Sony Sukhbir Singh, professor and chair of the department of obstetrics and gynaecology, at the University of Ottawa, said: “Uterine fibroids and endometriosis are very common conditions affecting millions of Canadians.
“Endometriosis, in particular, can be a very challenging and complex condition to treat, often resulting in years of delay to diagnosis.
“These conditions can cause debilitating symptoms such as pain and bleeding, impacting daily life and overall wellbeing for many girls, women and gender diverse individuals.”
Pregnancy
Pregnant women may reduce key health risk through more light exercise, study finds

Light exercise and less sitting may reduce pregnant women’s risk of serious blood pressure complications, according to a new study.
Researchers have proposed a daily activity and sleep guide that they say was linked to a nearly 30 per cent lower risk of hypertensive disorders of pregnancy.
The suggested pattern includes fewer than eight hours of sedentary time, at least seven hours of light physical activity, around 22 minutes of more intense activity and nearly nine hours of sleep.
The University of Iowa-led study examined the daily behaviours of 470 pregnant women across all stages of pregnancy.
Participants wore monitors that measured physical activity over 24-hour periods and recorded how long they spent asleep.
Hypertensive disorders of pregnancy include chronic high blood pressure, gestational hypertension and pre-eclampsia.
Gestational hypertension is high blood pressure that develops during pregnancy, while pre-eclampsia is a potentially serious condition involving high blood pressure and signs that organs may be affected.
Sedentary behaviour means being mostly inactive, such as sitting or lying down.
Light physical activity can include casual walking, moving around the home or standing.
Moderate to vigorous activity includes movement such as brisk walking, where breathing and heart rate increase.
Kara Whitaker, associate professor in the department of health, sport, and human physiology at Iowa and corresponding author of the study, said: “We are identifying the optimal composition of movement behaviours across the day associated with the lowest risk of developing HDP and the most improved health outcomes.
“This blueprint holds for each and every trimester of pregnancy.”
Study participants were enrolled at sites in Iowa City, Pittsburgh and Morgantown, West Virginia.
The women wore activity and sleep monitors for at least one week during each trimester of pregnancy.
Four in five participants were non-Hispanic white and nearly a quarter lived in rural areas.
The data showed a steep rise in risk among pregnant women who were sedentary for more than 10 hours a day.
Women who increased light physical activity to at least four hours a day reduced their risk of hypertensive disorders of pregnancy to 15 per cent from 30 per cent.
Whitaker said: “Just moving around more seems to have significant health benefits.
“And I think it also may be a more feasible target for women who are pregnant who are not exercising regularly.”
The researchers said they were surprised that longer durations of moderate to vigorous physical activity did not appear to provide additional benefit.
Sleep beyond a certain duration also did not appear to bring major further benefits.
Whitaker said: “Through this study, we are providing evidence that reducing sedentary behaviour and engaging in light physical activity are important, and maybe more important, when it comes to pregnancy and health.”
The findings may be relevant beyond pregnancy because clinical research has shown that women who develop hypertensive disorders of pregnancy are more than twice as likely to develop heart disease later in life.
Cardiovascular disease includes conditions affecting the heart and blood vessels, such as heart disease and stroke.
Whitaker said: “We know that cardiovascular disease is the number one killer of women, and if we can intervene in pregnancy and prevent women from developing a hypertensive disorder of pregnancy, we are putting them on a better trajectory, away from cardiovascular disease and toward more optimal cardiovascular health.”
The study was published online on June 10.
A second study, published online on May 27, looked more closely at the ratio and type of sedentary behaviour and light physical activity linked to a lower risk of hypertensive disorders of pregnancy.
Whitaker is a lead co-author on that study.
Co-authors in the June 10 study include Alex Crisp, Jaemyung Kim, Karina Smith, Donna Santillan, Mark Santillan and Bridget Zimmerman, from Iowa; Jacob Gallagher, from Iowa State University; Melissa Jones, from Oakland University in Michigan; Bethany Barone Gibbs, Katrina Wilhite, Alexis Thrower and Iqra Sheikh, from West Virginia University; and Sabera Rahman, Janet Catov, Christopher Kline and Maisa Feghali, from the University of Pittsburgh.
The National Institutes of Health, the University of Iowa Institute for Clinical and Translational Science, the University of Pittsburgh Clinical and Translational Science Institute and the West Virginia Clinical and Translational Science Institute funded the research.
News
Femtech World Awards 2026: Winners revealed

We are excited to reveal the winners of the third annual Femtech World Awards.
The winners were announced at a virtual event this afternoon attended by shortlisted companies, along with sponsors and judges.
The event welcomed guests from the UK, Europe, Asia, Africa and North America.
Thank you to all 174 entries, as well as the sponsors for making the event possible.
See you in 2027!
Femtech World Awards 2026 Winners

Winner:
Shortlisted:
IVI RMA x Juno Genetics
Natural Cycles

Winner:
Highly commended:
U-Ploid
Shortlisted:
Hello Inside

Winner:
WISE HF, led by Prof. Mary Ryder
Highly commended:
Cardiac College for Women
Shortlisted:
Hyvelle Ferguson-Davis
CognitiveCare

Winner:
Highly commended:
Youterus
Shortlisted:
ŌURA

Winner:
Shortlisted:
LeanShield by ParrotPal Group
Perigen

Winner:
Shortlisted:
Body Moody
Looop

Winner:
Shortlisted:
Owning Your Menopause
Womeno

Winner:
Shortlisted:
The Blue Box
Celbrea

Winner:
Shortlisted:
HealCycle
Mor

Winner:
Shortlisted:
HRC Fertility
Mira
Motherhood
Expectations about sleep affect postpartum sleep quality, study finds

Pregnant women’s expectations about postpartum sleep may predict sleep quality after birth, outweighing prior sleep and psychiatric history, a study suggests.
The findings suggest attitudes and beliefs about sleep during pregnancy could be a modifiable risk factor for postpartum sleep concerns.
They also indicate that, among women expecting the poorest sleep, higher postpartum anxiety may further worsen sleep quality.
Sammy Dhaliwal, lead author is clinical health psychologist and research fellow in the department of obstetrics and gynaecology at the Perelman School of Medicine at the University of Pennsylvania.
Dhaliwal said: “Most pregnant women in our sample anticipated poor postpartum sleep before it occurred, and it was striking that those expectations predicted worse sleep outcomes even after accounting for factors such as prior sleep disorders, psychiatric history, and number of previous births.
“This suggests that attitudes and beliefs about sleep during pregnancy may represent a modifiable target for early intervention before postpartum sleep problems emerge.”
Sleep disturbance affects an estimated 60 to 80 per cent of postpartum women and is linked to a higher risk of depression and anxiety.
Researchers said it is often regarded as an expected part of life after childbirth rather than a health issue that may be addressed earlier.
The study enrolled 432 pregnant women at about 24 weeks of gestation, meaning around 24 weeks into pregnancy.
Participants completed measures of their expectations about postpartum sleep, current sleep quality using the Pittsburgh Sleep Quality Index, and mood using validated depression and anxiety scales.
Assessments were repeated at six, 12 and 24 weeks postpartum.
A subset of 49 women also wore wrist actigraphy devices at six to eight weeks postpartum.
Actigraphy uses a wearable device, similar to a watch, to estimate sleep and wake patterns based on movement.
The results showed that 70 per cent of pregnant women, or 301 of 432 participants, expected poor sleep in the postpartum period.
Researchers found that predicted sleep disruption during pregnancy was a significant predictor of postpartum sleep concerns.
Among first-time pregnant women without prior health concerns, those who expected greater sleep disturbance had significantly more disrupted sleep after birth, measured by both actigraphy and self-report.
Among women who expected the worst sleep quality, higher postpartum anxiety significantly worsened both measured sleep and self-reported sleep, independent of anxiety levels during pregnancy.
Dhaliwal said the findings point to two possible areas for intervention: addressing sleep-related beliefs during pregnancy and treating postpartum anxiety.
Dhaliwal said: “Postpartum sleep disruption is often treated only after problems develop, but our findings suggest there may be an opportunity to intervene earlier during pregnancy.
“Addressing sleep-related beliefs and postpartum anxiety during prenatal and postpartum care may help improve sleep and emotional well-being in new mothers.”
Menopause3 weeks agoPerimenopause misinformation ‘putting women at risk’
Hormonal health4 weeks agoNHS urged to update website following renaming of PCOS
News2 weeks agoWomen still being failed when they reach menopause, experts say
Entrepreneur3 weeks agoWomen’s Health Innovation Summit opens submissions for 2026 Innovation Showcase
Insight1 week agoBritish women among angriest in Europe, health survey reveals
News2 weeks agoThree menopause innovators shortlisted for Femtech World Award
Menopause3 weeks agoSweden eyes domestic production of oestrogen patches amid menopause treatment shortage
News3 weeks agoLow insulin diet and avoiding four food groups may prevent menopause weight gain





















